Business

India and US Poised to Strengthen Collaboration in Healthcare Security and Affordability: Indian Pharmaceutical Alliance

The United States continues to hold its position as the largest market for the Indian pharmaceutical industry. Experts in India are now anticipating enhanced collaboration opportunities between the two nations in healthcare security and affordability under the evolving global scenario.

• By Newsdesk
• New Delhi
• Jan 21, 2025

Business

The United States continues to hold its position as the largest market for the Indian pharmaceutical industry. Experts in India are now anticipating enhanced collaboration opportunities between the two nations in healthcare security and affordability under the evolving global scenario, noted Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA).

Commenting on the potential for bilateral cooperation, Jain said, “The relationship between India and the US has grown stronger over the years. Healthcare security and affordability are critical areas of focus, and there is a significant opportunity for India and the US to work together to advance these priorities.”

Jain highlighted that both nations recognize the importance of a resilient and diversified pharmaceutical supply chain, which has become even more relevant in the wake of global disruptions. He pointed to India’s Production Linked Incentive (PLI) Scheme for active pharmaceutical ingredients (APIs), which has shown promising early results. “A synergistic effort between India and the US can accelerate this initiative, bolstering self-reliance and enhancing healthcare security. As a trusted supplier of quality-assured medicines, India is pivotal in meeting healthcare needs, not just for the US but for the global market,” he stated.

Jain further underscored the potential for collaboration in pharmaceutical research, development, and manufacturing. “Healthcare can act as a cornerstone of the India-US partnership, helping both nations address common challenges such as supply chain resilience and security while advancing innovation in drug development,” he added.

Echoing similar sentiments, Biocon Chairperson Kiran Mazumdar-Shaw emphasized India’s role as a dependable supplier of essential medicines. In a recent post on social media platform X (formerly Twitter), Mazumdar-Shaw remarked, “India has established itself as a reliable supplier of essential medicines and has taken the lead in the manufacturing and export of generic drugs. I am confident that India can bridge gaps in unmet medical demand globally.”

With India’s robust pharmaceutical manufacturing capabilities and the US’s focus on healthcare reform, the partnership between the two countries could significantly impact global healthcare outcomes. Enhanced collaboration could pave the way for innovations in affordability and accessibility, ensuring that quality healthcare reaches more people worldwide.

(With inputs from ANI)